Jpmorgan Chase & CO Evogene Ltd. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Evogene Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,969 shares of EVGN stock, worth $28,590. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,969
Previous 39,430
62.04%
Holding current value
$28,590
Previous $29,000
68.97%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding EVGN
# of Institutions
25Shares Held
3.88MCall Options Held
400Put Options Held
0-
Silverarc Capital Management, LLC3.08MShares$5.88 Million0.57% of portfolio
-
Morgan Stanley New York, NY218KShares$417,2490.0% of portfolio
-
Eidelman Virant Capital117KShares$223,4700.07% of portfolio
-
Lpl Financial LLC Fort Mill, SC67.3KShares$128,6090.0% of portfolio
-
Ubs Group Ag66KShares$126,0690.0% of portfolio
About Evogene Ltd.
- Ticker EVGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,202,000
- Market Cap $78.7M
- Description
- Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding ...